Evidence map›Paper›PMID 35296236›Full record

ArticleBMC genomics2022

Extensive evaluation of ATAC-seq protocols for native or formaldehyde-fixed nuclei.

Hao Zhang, Michael E Rice, Joseph W Alvin, Dominique Farrera-Gaffney, James J Galligan, Michael D L Johnson, Darren A Cusanovich

Abstract read
In one paragraph

Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. ATAC-seq in Emerging Model Organisms: Challenges and Strategies.Journal of experimental zoology. Part B, Molecular and developmental evolution · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao ZhangDepartment of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
Michael E RiceDepartment of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
Joseph W AlvinDepartment of Immunobiology, University of Arizona, Tucson, AZ, USA.
Dominique Farrera-GaffneyDepartment of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA.
James J GalliganDepartment of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA.
Michael D L JohnsonDepartment of Immunobiology, University of Arizona, Tucson, AZ, USA.
Darren A CusanovichDepartment of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA. darrenc@arizona.edu.

Funding

SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI DEAN BILLHEIMER · 1994 to 2026
$36.7M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Establishing Glyoxalase 2 as a Viable Target for the Treatment of Disease [Equipment Supplement]R35GM137910 · NIGMS · UNIVERSITY OF ARIZONA · PI GALLIGAN, JAMES J · 2020 to 2024
$2.1M
Beyond Pseudotime: Enhanced Single-cell Genomics Tools for Understanding the Temporal Dynamics of Development and DiseaseR35GM137896 · NIGMS · UNIVERSITY OF ARIZONA · PI CUSANOVICH, DARREN A · 2020 to 2024
$1.8M
NIEHS NIH HHS P30 ES006694NIEHS NIH HHS T32 ES007091NIGMS NIH HHS R35 GM137896NIGMS NIH HHS R35 GM137910
6 · The paper itself

Abstract

backgroundThe "Assay for Transposase Accessible Chromatin sequencing" (ATAC-seq) is an efficient and easy to implement protocol to measure chromatin accessibility that has been widely used in multiple applications studying gene regulation. While several modifications or variants of the protocol have been published since it was first described, there has not yet been an extensive evaluation of the effects of specific protocol choices head-to-head in a consistent experimental setting. In this study, we tested multiple protocol options for major ATAC-seq components (including three reaction buffers, two reaction temperatures, two enzyme sources, and the use of either native or fixed nuclei) in a well-characterized cell line. With all possible combinations of components, we created 24 experimental conditions with four replicates for each (a total of 96 samples). In addition, we tested the 12 native conditions in a primary sample type (mouse lung tissue) with two different input amounts. Through these extensive comparisons, we were able to observe the effect of different ATAC-seq conditions on data quality and to examine the utility and potential redundancy of various quality metrics.

resultsIn general, native samples yielded more peaks (particularly at loci not overlapping transcription start sites) than fixed samples, and the temperature at which the enzymatic reaction was carried out had a major impact on data quality metrics for both fixed and native nuclei. However, the effect of various conditions tested was not always consistent between the native and fixed samples. For example, the Nextera and Omni buffers were largely interchangeable across all other conditions, while the THS buffer resulted in markedly different profiles in native samples. In-house and commercial enzymes performed similarly.

conclusionsWe found that the relationship between commonly used measures of library quality differed across temperature and fixation, and so evaluating multiple metrics in assessing the quality of a sample is recommended. Notably, we also found that these choices can bias the functional class of elements profiled and so we recommend evaluating several formulations in any new experiments. Finally, we hope the ATAC-seq workflow formulated in this study on crosslinked samples will help to profile archival clinical specimens.

Indexed as

Cell NucleusChromatin Immunoprecipitation SequencingAnimalsChromatinFormaldehydeMiceSequence Analysis, DNAChromatinFormaldehydeATAC-seqChromatin accessibilityQuality controlTn5Transcription factor

Identifiers

PMID35296236
PMCPMC8928671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.